Applies to drotrecogin alfa: parenteral diluted iv solutions, parenteral powder for injection
Side effects include:
Bleeding (e.g., ecchymoses, GI bleeding, intracranial hemorrhage). 
Applies to drotrecogin alfa: intravenous powder for injection
The most common side effect associated with drotrecogin alfa has been bleeding.[Ref]
Hematologic side effects have most commonly included bleeding (25% vs 18% with placebo).  The majority of events were ecchymoses or gastrointestinal tract bleeding.  Serious bleeding has been reported in 3.5% of patients (vs 2% with placebo) and included intracranial hemorrhage, life threatening hemorrhage, and any event requiring 3 or more units of packed red blood cells per days for 2 consecutive days.[Ref]
Serious bleeding events have been reported at the following sites:  Gastrointestinal, intra-abdominal, intrathoracic, retroperitoneal, intracranial, genitourinary, skin or soft tissues.[Ref]
1. Bernard GR,  Vincent JL,  Laterre PF, et al. "Efficacy and safety of recombinant human activated protein C for severe sepsis." N Engl J Med 344 (2001): 699-709
2. "Product Information. Xigris (drotrecogin alfa)." Lilly, Eli and Company, Indianapolis, IN. 
Not all side effects for drotrecogin alfa may be reported. You should always consult a doctor or healthcare professional for medical advice. Side effects can be reported to the FDA here.
